Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Anas Younes, Patrick Hilden, Bertrand Coiffier, et al.
Annals of Oncology (2017) Vol. 28, Iss. 7, pp. 1436-1447
Open Access | Times Cited: 312

Showing 1-25 of 312 citing articles:

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 14, pp. 1428-1439
Open Access | Times Cited: 688
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam, Mary Ann Anderson, Christiane Pott, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 13, pp. 1211-1223
Open Access | Times Cited: 379
Follicular lymphoma
Antonino Carbone, Sandrine Roulland, Annunziata Gloghini, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 214
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
Abraham S. Kanate, Navneet S. Majhail, Bipin N. Savani, et al.
Biology of Blood and Marrow Transplantation (2020) Vol. 26, Iss. 7, pp. 1247-1256
Open Access | Times Cited: 212
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington, et al.
Annals of Oncology (2018) Vol. 29, Iss. 11, pp. 2163-2174
Open Access | Times Cited: 180
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov, Alexander Bagaev, María V. Revuelta, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1468-1489
Open Access | Times Cited: 175
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Christoph Kornauth, Tea Pemovska, Gregory I. Vladimer, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 372-387
Open Access | Times Cited: 132
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Ramon Barajas, Letterio S. Politi, Nicoletta Anzalone, et al.
Neuro-Oncology (2021)
Open Access | Times Cited: 115
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B. Staber, Marco Herling, Mar Bellido, et al.
Blood (2019) Vol. 134, Iss. 14, pp. 1132-1143
Open Access | Times Cited: 123
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)
Nandita M. deSouza, Eric Achten, Ángel Alberich‐Bayarri, et al.
Insights into Imaging (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 80
Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma
Sarah Haebe, Tanaya Shree, Anuja Sathe, et al.
Blood (2021) Vol. 137, Iss. 21, pp. 2869-2880
Open Access | Times Cited: 73
PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology
Valentin Duclos, Alex Iep, Léa Gomez, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4159-4159
Open Access | Times Cited: 61
Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4690-4695
Open Access | Times Cited: 57
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Anushka Walia, Jordan Tuia, Vinay Prasad
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 885-895
Open Access | Times Cited: 28
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study
Yan Gao, Haixia He, Xue‐Ping Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
T-cell prolymphocytic leukemia, a case report and review of the literature
Luis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel Juárez‐Salcedo, Javier Loscertales, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2025) Vol. 33, Iss. 3, pp. 505-517
Closed Access | Times Cited: 1
How I treat primary mediastinal B-cell lymphoma
Lisa Giulino‐Roth
Blood (2018) Vol. 132, Iss. 8, pp. 782-790
Open Access | Times Cited: 67
Breast Implant–associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms
Bhupinder Sharma, Amanda Jürgensen-Rauch, Erika Pace, et al.
Radiographics (2020) Vol. 40, Iss. 3, pp. 609-628
Closed Access | Times Cited: 54
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant
Wei Jiang, Leighton Clancy, Selmir Avdic, et al.
Blood Advances (2022) Vol. 6, Iss. 17, pp. 4949-4966
Open Access | Times Cited: 31
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)
Fabien Ricard, Bruce D. Cheson, Sally F. Barrington, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 1, pp. 102-108
Open Access | Times Cited: 30
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Tingyu Wang, Xiuhua Sun, Lihua Qiu, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 8, pp. 1440-1449
Open Access | Times Cited: 19
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects
Akram Al‐Ibraheem, Ahmed Saad Abdlkadir, Malik E. Juweid, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1063-1063
Open Access | Times Cited: 19
Global Challenges for Cancer Imaging
Heinz‐Peter Schlemmer, Leonardo Kayat Bittencourt, Melvin D’Anastasi, et al.
Journal of Global Oncology (2017), Iss. 4, pp. 1-10
Open Access | Times Cited: 59
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Marcus Unterrainer, Michael Ruzicka, Matthias P. Fabritius, et al.
European Radiology Experimental (2020) Vol. 4, Iss. 1
Open Access | Times Cited: 49
FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
Conrad‐Amadeus Voltin, Jasmin Mettler, Jirka Grosse, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 601-601
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top